Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport
View through CrossRef
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low‐density lipoprotein receptor (LDLRs) molecules expressed on the cell surface. Gene inactivation of PCSK9 reduces the areas of atherosclerotic lesions in mice, and the effect is mainly dependent on LDLRs. Furthermore, a positive relationship between PCSK9 and cholesterol accumulation in the wall of the aorta has been established. However, the mechanism remains unknown. As PCSK9 is mainly expressed in atherosclerotic plaque and in the liver, we hypothesize that PCSK9 might increase oxidized LDL uptake and impair macrophage‐mediated reverse cholesterol transport, contributing to the development of atherosclerosis.
Title: Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport
Description:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low‐density lipoprotein receptor (LDLRs) molecules expressed on the cell surface.
Gene inactivation of PCSK9 reduces the areas of atherosclerotic lesions in mice, and the effect is mainly dependent on LDLRs.
Furthermore, a positive relationship between PCSK9 and cholesterol accumulation in the wall of the aorta has been established.
However, the mechanism remains unknown.
As PCSK9 is mainly expressed in atherosclerotic plaque and in the liver, we hypothesize that PCSK9 might increase oxidized LDL uptake and impair macrophage‐mediated reverse cholesterol transport, contributing to the development of atherosclerosis.
Related Results
PCSK9 Inhibitors: Pharmacology and Therapeutic Potential
PCSK9 Inhibitors: Pharmacology and Therapeutic Potential
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is a proteolytic enzyme that indirectly regulates serum LDL cholesterol by destroying LDL receptors. In clinical studies, the ...
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Background—
Homozygous familial hypercholesterolemia is a rare, serious disorder with a substantial reduction in low-density lipoprotein (LDL) receptor function, severe...
Discovery of (2‐(4‐Substituted phenyl)quinolin‐4‐yl)(4‐isopropylpiperazin‐1‐yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Discovery of (2‐(4‐Substituted phenyl)quinolin‐4‐yl)(4‐isopropylpiperazin‐1‐yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
AbstractInhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an increasingly important role in the treatment of hyperlipidemia. In pursuit of potent small mole...
Activation of Adiponectin Receptors Induces Proprotein Convertase Subtilisin Kexin Type 9 Expression by Activating PPARgamma Pathway
Activation of Adiponectin Receptors Induces Proprotein Convertase Subtilisin Kexin Type 9 Expression by Activating PPARgamma Pathway
Adiponectin is a hormone derived from adipose tissues. Reduced adiponectin levels have been determined to be associated with the occurrence of obesity‐linked diseases including ins...
Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report
Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report
Background:
Managing hypertriglyceridemia-induced acute pancreatitis (HTG-AP)
can be challenging, particularly due to the need for rapid triglyceride reduction to below
500mg/dL (5...
Directional and balancing selection on proprotein convertase subtilisin/kexin type 6 (PCSK6)
Directional and balancing selection on proprotein convertase subtilisin/kexin type 6 (PCSK6)
The selective pressures challenging the human population leave genetic signatures. This study was designed to detect positive and balancing selection on the proprotein convertase s...
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus
Background Low-density lipoprotein (LDL) levels are increased by proprotein convertase subtilisin kexin 9 (PCSK9) which targets the LDL receptor. We recently reported that PCSK9 am...
Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome
Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome
Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS).
...